Italia markets close in 8 hours 7 minutes

Scinai Immunotherapeutics Ltd. (SCNI)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,4011-0,0489 (-10,87%)
Alla chiusura: 04:00PM EDT
0,4049 +0,00 (+0,95%)
Dopo ore: 07:49PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,4500
Aperto0,4575
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,3900 - 0,4649
Intervallo di 52 settimane0,3900 - 22,7000
Volume83.875
Media Volume2.732
Capitalizzazione2,331M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-16,0000
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023

    Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trialsJERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place October 24 to 26. Several members of Scinai’s executive leadership team will

  • GlobeNewswire

    Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

    JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS

  • GlobeNewswire

    Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

    JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that it has entered into a definitive agreement for the purchase and sale of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), ea